Organogenesis (ORGO) Competitors

$1.49 -0.04 (-2.61%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.50 +0.01 (+0.81%)

As of 09/11/2026 07:50 PM Eastern

ORGO vs. RIGL, FTH, DBVT, ACRS, and SLN

Should you buy Organogenesis stock or one of its competitors? Organogenesis's main competitors and comparable companies include Rigel Pharmaceuticals (RIGL), Sensei Biotherapeutics (FTH), DBV Technologies (DBVT), Aclaris Therapeutics (ACRS), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Organogenesis compare to Rigel Pharmaceuticals?

Organogenesis (NASDAQ:ORGO) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Organogenesis presently has a consensus target price of $4.33, indicating a potential upside of 190.83%. Rigel Pharmaceuticals has a consensus target price of $59.00, indicating a potential upside of 24.89%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has lower revenue, but higher earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.34	$37.03M	-$0.86	N/A
Rigel Pharmaceuticals	$276.79M	3.16	$367.02M	$16.32	2.89

Rigel Pharmaceuticals has a net margin of 116.30% compared to Organogenesis' net margin of -19.94%. Rigel Pharmaceuticals' return on equity of 22.95% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.89 beat Rigel Pharmaceuticals' score of 0.94 indicating that Organogenesis is being referred to more favorably in the media.

Company	Overall Sentiment
Organogenesis	Very Positive
Rigel Pharmaceuticals	Positive

Organogenesis has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Organogenesis on 11 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Sensei Biotherapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Organogenesis	-19.94%	-23.89%	-11.13%

In the previous week, Sensei Biotherapeutics had 8 more articles in the media than Organogenesis. MarketBeat recorded 9 mentions for Sensei Biotherapeutics and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.89 beat Sensei Biotherapeutics' score of 0.58 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Sensei Biotherapeutics	Positive
Organogenesis	Very Positive

Organogenesis has higher revenue and earnings than Sensei Biotherapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Organogenesis	$564.17M	0.34	$37.03M	-$0.86	N/A

Sensei Biotherapeutics presently has a consensus price target of $55.00, indicating a potential upside of 46.90%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 190.83%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Organogenesis beats Sensei Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Organogenesis compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DBV Technologies currently has a consensus target price of $48.50, indicating a potential upside of 309.28%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 190.83%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Organogenesis has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	132.11	-$146.95M	-$3.51	N/A
Organogenesis	$564.17M	0.34	$37.03M	-$0.86	N/A

DBV Technologies has a beta of -0.95, meaning that its share price is 195% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Organogenesis has a net margin of -19.94% compared to DBV Technologies' net margin of -3,506.53%. Organogenesis' return on equity of -23.89% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Organogenesis	-19.94%	-23.89%	-11.13%

In the previous week, DBV Technologies had 2 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.89 beat DBV Technologies' score of 1.07 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
DBV Technologies	Positive
Organogenesis	Very Positive

Summary

Organogenesis beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organogenesis has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	95.00	-$64.92M	-$0.58	N/A
Organogenesis	$564.17M	0.34	$37.03M	-$0.86	N/A

Organogenesis has a net margin of -19.94% compared to Aclaris Therapeutics' net margin of -921.50%. Organogenesis' return on equity of -23.89% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Organogenesis	-19.94%	-23.89%	-11.13%

In the previous week, Aclaris Therapeutics had 5 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 1 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.89 beat Aclaris Therapeutics' score of 0.69 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Aclaris Therapeutics	Positive
Organogenesis	Very Positive

Aclaris Therapeutics presently has a consensus price target of $11.33, indicating a potential upside of 113.03%. Organogenesis has a consensus price target of $4.33, indicating a potential upside of 190.83%. Given Organogenesis' higher possible upside, analysts plainly believe Organogenesis is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Aclaris Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Summary

Organogenesis beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Organogenesis compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

In the previous week, Silence Therapeutics and Silence Therapeutics both had 1 articles in the media. Organogenesis' average media sentiment score of 1.89 beat Silence Therapeutics' score of 1.18 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Organogenesis	Very Positive

Organogenesis has a net margin of -19.94% compared to Silence Therapeutics' net margin of -8,943.86%. Organogenesis' return on equity of -23.89% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Organogenesis	-19.94%	-23.89%	-11.13%

Silence Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organogenesis has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$615K	1,274.67	-$88.61M	-$1.28	N/A
Organogenesis	$564.17M	0.34	$37.03M	-$0.86	N/A

Silence Therapeutics presently has a consensus target price of $53.50, indicating a potential upside of 310.91%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 190.83%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Silence Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Organogenesis beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$196.87M	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-1.73	14.25	275.24	25.29
Price / Sales	0.34	1,473.06	655.99	98.94
Price / Cash	2.36	106.68	77.04	51.44
Price / Book	0.63	15.12	10.33	6.20
Net Income	$37.03M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-12.87%	-4.34%	-3.32%	-2.35%
1 Month Performance	-17.68%	-0.02%	-0.41%	-2.77%
1 Year Performance	-69.78%	40.64%	19.21%	7.63%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	2.0878 of 5 stars	$1.49 -2.6%	$4.33 +190.8%	-70.4%	$196.87M	$564.17M	N/A	950	Positive News
RIGL Rigel Pharmaceuticals	4.5911 of 5 stars	$46.63 +1.0%	$59.00 +26.5%	+24.9%	$862.60M	$294.28M	2.86	160	Positive News Analyst Upgrade
FTH Sensei Biotherapeutics	4.1408 of 5 stars	$33.47 +2.1%	$55.00 +64.3%	N/A	$861.51M	N/A	N/A	40	News Coverage Analyst Forecast
DBVT DBV Technologies	3.4504 of 5 stars	$13.41 -3.0%	$48.50 +261.8%	+21.0%	$844.48M	$5.64M	N/A	80	News Coverage Positive News Analyst Forecast
ACRS Aclaris Therapeutics	2.2877 of 5 stars	$6.00 -0.9%	$11.33 +89.0%	+170.1%	$839.62M	$7.83M	N/A	100	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. RIGL, FTH, DBVT, ACRS, and SLN

How does Organogenesis compare to Rigel Pharmaceuticals?

Summary

How does Organogenesis compare to Sensei Biotherapeutics?

Summary

How does Organogenesis compare to DBV Technologies?

Summary

How does Organogenesis compare to Aclaris Therapeutics?

Summary

How does Organogenesis compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. RIGL, FTH, DBVT, ACRS, and SLN

How does Organogenesis compare to Rigel Pharmaceuticals?

Do insiders and institutionals believe in ORGO or RIGL?

Do analysts prefer ORGO or RIGL?

Which has preferable valuation & earnings, ORGO or RIGL?

Is ORGO or RIGL more profitable?

Does the media favor ORGO or RIGL?

Which has more volatility and risk, ORGO or RIGL?

Summary

How does Organogenesis compare to Sensei Biotherapeutics?

Which has more risk and volatility, FTH or ORGO?

Is FTH or ORGO more profitable?

Does the media refer more to FTH or ORGO?

Which has better earnings & valuation, FTH or ORGO?

Do analysts rate FTH or ORGO?

Do institutionals & insiders have more ownership in FTH or ORGO?

Summary

How does Organogenesis compare to DBV Technologies?

Do insiders & institutionals have more ownership in DBVT or ORGO?

Do analysts recommend DBVT or ORGO?

Which has preferable valuation & earnings, DBVT or ORGO?

Which has more risk & volatility, DBVT or ORGO?

Is DBVT or ORGO more profitable?

Does the media refer more to DBVT or ORGO?

Summary

How does Organogenesis compare to Aclaris Therapeutics?

Do insiders and institutionals have more ownership in ACRS or ORGO?

Which has stronger valuation and earnings, ACRS or ORGO?

Is ACRS or ORGO more profitable?

Does the media refer more to ACRS or ORGO?

Do analysts recommend ACRS or ORGO?

Which has more volatility & risk, ACRS or ORGO?

Summary

How does Organogenesis compare to Silence Therapeutics?

Does the media refer more to SLN or ORGO?

Is SLN or ORGO more profitable?

Which has more volatility & risk, SLN or ORGO?

Do insiders & institutionals have more ownership in SLN or ORGO?

Which has stronger valuation & earnings, SLN or ORGO?

Do analysts prefer SLN or ORGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools